Comfort Comtrade (534691)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Sales growth of 1007.46% indicates a sharp expansion in business activity
• ROCE of 12.73% suggests some positive operating-level return on capital employed
• Book value of ₹14.91 provides tangible backing; price is only 1.58 times book
• Dividend yield of 3.57% offers some cash return, assuming it is sustainable

Concerns

• ROE is -67.99% and latest quarter shows net loss of ₹4 crore on ₹22 crore sales
• Profit growth of -487.83% and P/E of 0.00 indicate no meaningful earnings
• Piotroski F-Score of 4/9 signals weak financial health
• Dividend looks fragile given ongoing losses; promoter holding data is unavailable

AI Analysis

This is not the sort of business I can understand or trust. Comfort Comtrade wears the label of financial services, but with a market cap of just ₹24 crore it is a micro-cap with no identifiable competitive advantage. The numbers tell a sobering story: return on equity is -67.99%, meaning management is destroying shareholder capital, not compounding it. The latest quarter shows sales of ₹22 crore but a net loss of ₹4 crore. A 1007.46% sales growth figure sounds exciting until you notice profit growth at -487.83%; growth without profits is often a treadmill, not a business. The Piotroski F-Score of 4 out of 9 confirms weak financial health. Book value is ₹14.91 per share, yet the market is asking ₹23.61, a P/B of 1.58; paying a premium for a business earning negative returns is something I will never do. The dividend yield of 3.57% is eye-catching, but with losses, that dividend looks fragile. ROCE of 12.73% is inconsistent with the ROE and likely distorted by a small capital base or unusual items. With insufficient data on promoter holding and a FairStock score of insufficient data, there is no margin of safety. I prefer businesses with predictable earnings, pricing power, and high returns on tangible capital. This appears to be a speculative, low-quality financial stock, perhaps an attempted turnaround, but the evidence does not justify the risk. As Graham would say, price is what you pay, value is what you get; here the value is unclear and the price is not cheap enough. I would keep this on the monitor list, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer